Biotech Growth Trust logo

BIOG - Biotech Growth Trust Share Price

1344p -98.0  -6.8%

Last Trade - 05/03/21

Sector
Financials
Size
Mid Cap
Market Cap £557.2m
Enterprise Value £581.6m
Revenue £285.6m
Position in Universe th / 1809
Bullish
Bearish
Unlock BIOG Revenue
Momentum
Relative Strength (%)
1m -20.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -23.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
221.2 -125.3 103.5 -24.1 26.7 66.0 -21.5%
+158.8 +247.9
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2020, TheBiotech Growth Trust Plc revenues increased from -£19.9M to£199.7M. Net income totaled £178.2M vs. loss of £22.4M.Revenues reflect (Losses)/gains on investments held atincrease from -£18.9M to £197.2M, Realized Foreign ExchangeG/L - Capital increase from -£1.7M to £2M. Net Incomereflects Other Expenses decrease of 23% to £235K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIOG Revenue Unlock BIOG Revenue

Net Income

BIOG Net Income Unlock BIOG Revenue

Normalised EPS

BIOG Normalised EPS Unlock BIOG Revenue

PE Ratio Range

BIOG PE Ratio Range Unlock BIOG Revenue

Dividend Yield Range

BIOG Dividend Yield Range Unlock BIOG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIOG EPS Forecasts Unlock BIOG Revenue
Profile Summary

The Biotech Growth Trust PLC is an investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies. The Company will not invest more than 15%, in aggregate, of the value of its gross assets in other closed ended investment companies (including investment trusts) listed on the London Stock Exchange. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. The Company will not invest more than 10% of the value of its gross assets in direct unquoted investments at the time of acquisition. OrbiMed Capital LLC is its portfolio manager. Frostrow Capital LLP is its alternative investment fund manager.

Directors
Last Annual March 31st, 2020
Last Interim September 30th, 2020
Incorporated May 20, 1997
Public Since June 23, 1997
No. of Shareholders: n/a
No. of Employees: n/a
Sector Financials
Industry Collective Investments
Index FTSE All Share , FTSE All-share - Financials Price Return Gbp End Of Day, FTSE All-share - Equity Investment Instruments Price Return Gbp End Of Day, FTSE Smallcap ,
Exchange London Stock Exchange (Full)
Shares in Issue 41,459,769
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIOG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIOG
Upcoming Events for BIOG
Frequently Asked Questions for Biotech Growth Trust
What is the Biotech Growth Trust share price?

As of 05/03/21, shares in Biotech Growth Trust are trading at 1344p, giving the company a market capitalisation of £557.2m. This share price information is delayed by 15 minutes.

How has the Biotech Growth Trust share price performed this year?

Shares in Biotech Growth Trust are currently trading at 1344p and the price has moved by 36.59% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biotech Growth Trust price has moved by 29.7% over the past year.

What are the analyst and broker recommendations for Biotech Growth Trust?

Of the analysts with advisory recommendations for Biotech Growth Trust, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biotech Growth Trust is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biotech Growth Trust next release its financial results?

Biotech Growth Trust is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Biotech Growth Trust dividend yield?

Biotech Growth Trust does not currently pay a dividend.

Does Biotech Growth Trust pay a dividend?

Biotech Growth Trust does not currently pay a dividend.

When does Biotech Growth Trust next pay dividends?

Biotech Growth Trust does not currently pay a dividend.

How do I buy Biotech Growth Trust shares?

To buy shares in Biotech Growth Trust you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biotech Growth Trust?

Shares in Biotech Growth Trust are currently trading at 1344p, giving the company a market capitalisation of £557.2m.

Where are Biotech Growth Trust shares listed? Where are Biotech Growth Trust shares listed?

Here are the trading details for Biotech Growth Trust:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: BIOG
What kind of share is Biotech Growth Trust?

We were not able to load our ranking data for Biotech Growth Trust

Is there a Biotech Growth Trust share price forecast 2021?

We were not able to load any forecast data for Biotech Growth Trust.

How can I tell whether the Biotech Growth Trust share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotech Growth Trust. Over the past six months, the relative strength of its shares against the market has been 0.76%. At the current price of 1344p, shares in Biotech Growth Trust are trading at -4.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biotech Growth Trust PE Ratio?

The Biotech Growth Trust PE ratio based on its reported earnings over the past 12 months is 2.07. The shares are currently trading at 1344p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Biotech Growth Trust?

We were unable to find the directors for Biotech Growth Trust.

Who are the major shareholders of Biotech Growth Trust?

Here are the top five shareholders of Biotech Growth Trust based on the size of their shareholding:

Hargreaves Lansdown Asset Management Limited Investment Advisor
Percentage owned: 10.13% (4.20m shares)
Border to Coast Pensions Partnership Ltd Pension Fund
Percentage owned: 5.76% (2.39m shares)
Rathbone Unit Trust Management Limited Investment Advisor/Hedge Fund
Percentage owned: 5.56% (2.30m shares)
Charles Stanley & Co. Limited Investment Advisor
Percentage owned: 4.29% (1.78m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 3.52% (1.46m shares)
Similar to BIOG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.